>Are you thinking competition from future DTIs and factor Xa inhibitors?<
Yes, of course. Moreover, the new genetic test for P450 is potentially problematic for the ARYX drug. You must have noticed how uncomfortable management was in addressing this issue on the CC.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”